Cleveland Clinic Main Campus is recruiting for a clinical research study that being done to evaluate the safety and effectiveness of Boston Scientific’s implantable DBS system in advanced PD patients with levodopa-responsive PD that is not being adequately controlled by medication. The goal of this system is to improve the number of waking hours per day with good symptom control and no troublesome dyskinesia (involuntary movements).
Approximately 310 PD patients are being recruited for this trial with approximately ten (10) anticipated at the Cleveland Clinic Main Campus.
The study involves approximately 12 scheduled visits to the Cleveland Clinic Main Campus during Year 1with yearly visits through Year 5.
Main Inclusion Criteria (patients who may be eligible to participate)
- Between the ages of 22-75
- Diagnosed with PD at least five (5) years ago
- Have symptoms of resting tremor (trembling or shaking), rigidity (stiffness) or bradykinesia (slowness of movement)
- Willing to travel to CCF main campus for frequent visits
Main Exclusion Criteria (patients who may not be eligible to participate)
- Ay medical or neurological condition that puts you at surgical risk
- Any significant psychiatric condition
- Current substance abuse
If you are interested in learning more about this trial, please contact study coordinator Alexandria Wyant at 216.444.1179. or email firstname.lastname@example.org and reference study: INTREPID
You can also find additional information on this trial at clinicaltrials.gov:
You can also download our flyer below.